Subject:
All Disciplines Arts & Humanities Biology & Life Sciences Business & Economics Chemistry & Materials Science Computer Science & Mathematics Engineering Environmental & Earth Sciences Medicine & Pharmacology Physical Sciences Public Health & Healthcare Social Sciences
Sort:
Hottest Latest Alphabetical (A-Z) Alphabetical (Z-A)
Type:
All Topic Review Biography
Topic Review
Treatment for Lung Carcinoids
Lung carcinoids are divided into typical and atypical. Most tumors are slow-growing yet have malignant potential, which is more common in patients harboring atypical carcinoids. Most patients with lung carcinoids are diagnosed before the occurrence of distant metastases. Surgery is curative in most of these cases. In individuals with distant metastases, the treatment is more controversial. A watch-and-wait policy has been proposed in asymptomatic individuals with a low proliferative rate. Possible treatment options include somatostatin analogues, chemotherapy, mTOR inhibitors, and radionuclide therapy with 177Lu-DOTA-octreotate, depending on somatostatin receptor expression, proliferative rate, bone marrow and kidney function, and the patient’s general health.
  • 179
  • 04 Dec 2023
Topic Review
Treatment for Itch in Atopic Dermatitis
This entry briefly describes the recent drugs for the treatment of atopic itch.
  • 381
  • 25 Nov 2021
Topic Review
Treatment for Central Serous Chorioretinopathy
Central serous chorioretinopathy (CSC) is a controversial disease both in terms of clinical classification and choice of therapeutic strategy. Choroidal layers, retinal pigment epithelium (RPE), photoreceptors, and retina are involved to varying degrees. 
  • 579
  • 18 Mar 2021
Topic Review
Treatment for Pseudomonas aeruginosa Infections
Pseudomonas aeruginosa is a ubiquitous Gram-negative bacterium renowned for its resilience and adaptability across diverse environments, including clinical settings, where it emerges as a formidable pathogen. Notorious for causing nosocomial infections, P. aeruginosa presents a significant challenge due to its intrinsic and acquired resistance mechanisms.
  • 248
  • 15 Nov 2023
Topic Review
Treatment Emergent Sexual Dysfunction
Antipsychotic medication can be often associated with sexual dysfunction (SD). Given its inti-mate nature, treatment emergent sexual dysfunction (TESD) remains underestimated in clinical practice. SD may cause diverse clinical alterations, such as low libido, difficulties in ejacu-lation, difficulties reaching orgasm, erection and vaginal lubrication, as well as men-strual alterations or gynecomastia. These alterations are mostly reversible with treatment discontinuation, except for priapism, which can require surgical interven-tion in some cases.
  • 1.2K
  • 29 Apr 2021
Topic Review
Treatment Drugs for Silicosis
Silicosis, characterized by irreversible pulmonary fibrosis, remains a major global public health problem. Cumulative studies are focusing on elucidating the pathogenesis of silicosis in order to identify preventive or therapeutic antifibrotic agents. However, the existing research on the mechanism of silica-dust-induced pulmonary fibrosis is only the tip of the iceberg and lags far behind clinical needs. Idiopathic pulmonary fibrosis (IPF), as a pulmonary fibrosis disease, also has the same problem.
  • 436
  • 15 Jun 2023
Topic Review
Treatment Combinations with DNA Vaccines
Metastatic castration-resistant prostate cancer (mCRPC) is a challenging disease to treat, with poor outcomes for patients. One antitumor vaccine, sipuleucel-T, has been approved as a treatment for mCRPC. DNA vaccines are another form of immunotherapy under investigation. DNA immunizations elicit antigen-specific T cells that cause tumor cell lysis, which should translate to meaningful clinical responses. They are easily amenable to design alterations, scalable for large-scale manufacturing, and thermo-stable for easy transport and distribution. Hence, they offer advantages over other vaccine formulations. However, clinical trials with DNA vaccines as a monotherapy have shown only modest clinical effects against tumors. Standard therapies for CRPC including androgen-targeted therapies, radiation therapy and chemotherapy all have immunomodulatory effects, which combined with immunotherapies such as DNA vaccines, could potentially improve treatment. In addition, many investigational drugs are being developed which can augment antitumor immunity, and together with DNA vaccines can further enhance antitumor responses in preclinical models.
  • 753
  • 20 Oct 2020
Topic Review
Treatment Approach of Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE), the prototype of systemic autoimmune diseases is characterized by extreme heterogeneity with a variable clinical course. Renal involvement may be observed and affects the outcome. Hydroxychloroquine should be administered to every lupus patient irrespective of organ involvement. Conventional immunosuppressive therapy includes corticosteroids, methotrexate, cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporine and tacrolimus. However, despite conventional immunosuppressive treatment, flares occur and broad immunosuppression is accompanied by multiple side effects. Flare occurrence, target organ involvement, side effects of broad immunosuppression and increased knowledge of the pathogenetic mechanisms involved in SLE pathogenesis as well as the availability of biologic agents has led to the application of biologic agents in SLE management. Biologic agents targeting various pathogenetic paths have been applied. B cell targeting agents have been used successfully. Belimumab, a B cell targeting agent, has been approved for the treatment of SLE. Rituximab, an anti-CD20 targeting agent is also used in SLE. Anifrolumab, an interferon I receptor-targeting agent has beneficial effects on SLE. In conclusion, biologic treatment is applied in SLE and should be further evaluated with the aim of a good treatment response and a significant improvement in quality of life.
  • 240
  • 10 Jul 2023
Topic Review
Treatment Approach for CA T-Cell Mediated Kidney Rejection
Chronic active T-cell mediated kidney rejection (CA TCMR) refers to the term that was described for the very first time during the XIII Banff Conference on Allograft Pathology in 2015 as a variant of kidney allogenic graft rejection associated with long-term graft loss. Since then, the scientific community tries to establish optimal scheme of diagnostic methods and therapeutic approach. 
  • 766
  • 27 Dec 2022
Topic Review
Treatment Algorithm in Cancer-Associated Thrombosis
Patients with cancer-associated thrombosis (CAT) are at high risk of recurrent venous thromboembolism (VTE) and major bleeding complications.
  • 309
  • 04 Jan 2022
  • Page
  • of
  • 1349
Featured Entry Collections
>>

Featured Books

>>
Encyclopedia of Social Sciences
Encyclopedia of COVID-19
Encyclopedia of Fungi
Encyclopedia of Digital Society, Industry 5.0 and Smart City
Video Production Service
Feedback